Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-2201 ADAPTABLE
2022-502103-30-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Feb 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Non-small cell lung cancer (NS-NSCLC) comparing paclitaxel + bevacizumab with paclitaxel + bevacizumab + Tecentriq (2 arms). Primary endpoint: Progression-free survival at 6 months (independent review). Planned start Feb 2023; status: authorised.
02
Drugs
atezolizumabbevacizumabpaclitaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2022-502103-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502103-30-00.